Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of AZD2171 in Recurrent or Persistent Ovarian, Peritoneal, or Fallopian Tube Cancer

NCT00278343 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00278343
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00278343 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of AZD2171 in Recurrent or Persistent Ovarian, Peritoneal, or Fallopian Tube Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2006
Completion date
January 15, 2018
Enrollment
74 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent fallopian tube cancer, recurrent ovarian epithelial cancer, recurrent primary peritoneal cavity cancer